Chinese biotechnology giant WuXi Apptec , will raise HK$7.70 billion ($980.93 million) through share placement, in a bid to ...

Growing Terumo has been busy building up its current facilities in Japan. After expanding the production lines at its site in Yamaguchi in 2023, the company is now working on adding new production ...

Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding ...

SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- WuXi XDC ("XDC"), a leading global CRDMO company dedicated to end-to-end bioconjugates services, announced that it received the Runner Up prize in the "Best ...

WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health ...

Biotech Candid's T-cell engager shopping spree rolls on with WuXi Biologics pact worth up to $925M By James Waldron Jan 7, 2025 8:42am WuXi Biologics Licensing deals Oncology bispecific antibodies ...

According to Chen, WuXi Biologics’ process technologies have been able to achieve demonstrable PPQ outcomes. Protein production costs per gram were reduced by nearly 70%, while advanced mass ...